cancer

Sanofi CEO Paul Hudson announced on Tuesday the creation of a nonprofit unit, Sanofi Global Health, which will provide 40 lower-income countries with access to 30 of the company’s “most essential medicines,” including cardiovascular, diabetes, tuberculosis, malaria and cancer treatments.

An accompanying press release said Sanofi Global Health will be the cornerstone of the Paris-based company’s corporate social responsibility strategy for “access to medicines, support for vulnerable…

The Access to Medicine (AtM) Foundation last week published a pediatric analysis of additional results from its 2021 AtM Index, finding just 7% of pharmaceutical companies’ R&D is for children under 12, despite significant gaps in treatment options for children.

The report praised GSK, Johnson & Johnson and Sanofi for being “the most active” in developing pediatric versions of products, and also named examples of drugs that “could each make a big difference” for LMICs: Eli…

Amgen will acquire California-based immuno-oncology and cancer therapy specialist Five Prime Therapeutics for approximately $1.9 billion, the companies announced last week.

Five Prime’s lead asset—an investigational “Phase 3 ready” antibody targeting gastric and other cancers—fits Amgen’s international expansion strategy: gastric cancer is prevalent in the Asia-Pacific region “where Amgen expects to generate significant volume growth in the coming years,” according to the press release…

The Clinton Health Access Initiative (CHAI) and the American Cancer Society (ACS) announced Monday that Biocon Biologics will join their Cancer Access Partnership (CAP), which aims to increase access to cancer treatments in low- and middle-income countries in Africa and Asia.

The addition of the Bangalore-based company—“India’s largest biopharma,” according to Biocon’s website—and an expanded portfolio of biosimilars from Pfizer will allow the partnership to offer affordable…

Pfizer announced Tuesday the launch of a new partnership with the Netherlands-based IDA Foundation to provide “equitable access to quality cancer treatments” in almost 70 low- and middle-income countries across Latin America, Asia, Africa and the Western Pacific region.

The agreement will allow developing country governments and non-governmental organizations to access 18 essential cancer treatments and 30 formulations from Pfizer’s portfolio, including options for treating breast,…

Covid-19 dominated the 39th J. P. Morgan Healthcare Conference (JPM), held virtually this week instead of at its customary haunt, San Francisco’s Westin St. Francis. Beyond much coronavirus chatter, the event also featured one major M&A announcement (Sanofi touting its $1 billion Kymab buy) and additional vaccine news from companies including GSK (for RSV), Moderna (for flu, HIV and Nipah) and Takeda (for dengue).

BioNTech CEO Uğur Şahin announced the German company’s plans to…

Evaluate issued its annual markets forecast Thursday, leading with the safe prediction that Covid-19 will continue to dominate interest: as a result of the pandemic, some pharma and biotech companies will start 2021 “bolstered by substantial financial support” and sporting “eye-watering” valuations.

The analyst group said Pfizer/BioNTech’s BNT162b2 shot will lead 2021 sales of Covid-19 vaccines but predicts that Moderna’s jab will be the market leader by 2026.

Evaluate expects…

In a further boost to its oncology pipeline, Merck announced last week that it will buy San Diego-based VelosBio for $2.75 billion in cash. The move adds another promising antibody-drug conjugate (ADC) to Merck’s portfolio, following a $1 billion equity investment in ADC specialist Seattle Genetics (now known as Seagen) in September.

In other acquisition news, Denmark’s Novo Nordisk announced plans last week to buy Emisphere Technologies for $1.35 billion. The deal includes the New…

Gilead will buy New Jersey’s Immunomedics for $21 billion, gaining access to the oncology specialist’s newly approved triple-negative breast cancer treatment, Trodelvy, the two companies said in a joint statement this week.

In other news, Merck will make a $1 billion equity investment in Seattle Genetics and pay up to $3.2 billion to the biotech to evaluate its antibody-drug conjugate ladiratuzumab vedotin (currently in Phase 2 trials) as a standalone cancer drug and in combination…

AstraZeneca announced this week that it will pay up to $6 billion in a development and commercialization deal with Daiichi Sankyo for DS-1062, the Japanese company’s antibody-drug conjugate (ADC) for non-small cell lung cancer and triple-negative breast cancer, currently in Phase 1. According to the press release, AstraZeneca will pay Daiichi Sankyo $1 billion upfront and up to $5 billion in additional regulatory and sales milestones for rights outside Japan.
 
The two companies…